Announcement
BOSTON, June 17, 2025 – CQDM is proud to announce the addition of three leading Japanese pharmaceutical companies—Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., and McQuade Center for Strategic Research and Development (MSRD), an indirect subsidiary of Otsuka Pharmaceutical Co., Ltd.—to its growing biopharmaceutical consortium. This strategic expansion strengthens CQDM’s industry reach and reinforces its mission to accelerate the development of innovative biopharmaceutical technologies in Canada through collaborative research. With this expansion, CQDM’s consortium now includes 11 global pharmaceutical companies.
The announcement was made at BIO 2025, bringing together several key stakeholders.
The inclusion of these globally recognized companies brings new perspectives, expertise, and resources to CQDM’s unique collaborative model, which unites industry, academia, and government to support cutting-edge research projects with high translational potential in Canada.
“We are thrilled to welcome Ono, Otsuka, and Daiichi Sankyo to the CQDM family,” said Véronique Dugas, President and CEO of CQDM. “Their commitment to innovation and global health aligns perfectly with our mission. Their participation will not only enhance our industrial network but also open new opportunities for international collaboration and co-development.”
“What sets CQDM apart is its exclusive consortium of leading global pharmaceutical companies, which provides a direct bridge between the Canadian life sciences ecosystem and international industry leaders. This model gives Canadian researchers and biotech companies unparalleled access to industry insight, mentorship, and commercialization pathways, helping to accelerate the translation of scientific discoveries into real-world therapies” said Jesse Paterson, Senior Director, Business development of CQDM
For more information about CQDM, our pharmaceutical members and how we create links between Canadian research the global pharmaceutical industry, please visit www.cqdm.org.
-30 –
About CQDM
Biopharma Innovation Facilitator
CQDM is a not-for-profit biopharmaceutical research consortium whose mission is to support and facilitate collaborative multi-stakeholder research and development aimed at accelerating the translation or transformation of innovative technologies into solutions to unmet medical needs, while generating significant benefits for the Quebec and Canadian economy. For more information, consult our website cqdm.org and join us on Twitter/X @CQDM_Canada and LinkedIn.
About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit daiichisankyo.com.
About Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd. delivers innovative therapies for patients worldwide. Upholding its philosophy of “Dedicated to the Fight against Disease and Pain,” Ono targets areas with unmet medical needs including oncology, immunology, and neurology, and fosters partnerships with academic and biotech organizations to accelerate drug discovery. Through its affiliate, Deciphera Pharmaceuticals, Ono is accelerating clinical development and commercial operations in the US and Europe to drive global business expansion and further its commitment to patient care. For more information, please visit the company’s website at ono-pharma.com.
About the McQuade Center for Strategic Research and Development (MSRD) and Otsuka Pharmaceutical Co., Ltd.
The mission of MSRD is to search for, identify, and fund innovative early-stage research and development programs that can change the landscape of treatments for mental illness, rare neurological diseases, autoimmune diseases and renal disorders. MSRD was established in 2019 by the Otsuka pharmaceutical business in the U.S. For more information about MSRD and Otsuka in North America, visit msrd-us.com, otsuka-us.com, and otsukacanada.com
Otsuka Pharmaceutical Co., Ltd., based in Japan, is a total healthcare company that focuses on each individual’s potential to enhance their well-being. Our medical-related business provides treatments and diagnostics for both physical and mental health. Our nutraceutical business supports daily health maintenance and improvement. Otsuka’s unique products and services are based on scientific evidence, under the guidance of our corporate philosophy: Otsuka-people creating new products for better health worldwide. For further information, visit www.otsuka.co.jp/en/
For further information:
Julia Serafino
CQDM Marketing and Communications Manager
438-543-9498
[email protected]
